HyperMed

GBP Capital's second investment was made in February 2007 in HyperMed. GBP provided a $5 million Series A investment. Proceeds from this financing will be used to launch HyperMed's flagship hyperspectral imaging diagnostic device, OxyVu-1, in the second half of 2007.

HyperMed believes that the better assessment of tissue oxygenation with OxyVu-1 will lead to improved health outcomes for people suffering from diabetic foot ulcers (DFU) and peripheral vascular disease (PAD), thereby substantially reducing amputations. The OxyVu-1 device provides quantitative measurements of oxy-hemoglobin (HT-Oxy), deoxy-hemoglobin (HT-Deoxy) and oxygen saturation (HT-Sat) in an easy to use visual format. The non-invasive OxyVu-1 Hyperspectral Oxygenation Measurement System is immediately available to provide healthcare professionals a clinically validated map of tissue oxygenation, which HyperMed believes will greatly improve the quality of life and cost efficiency of care among this patient population.

Hyperspectral Technology (HT), originally developed by the US Department of Defense has recently been applied to the study of physiologic and pathologic changes in animal and human tissue by HyperMed. This technology provides previously unavailable diagnostic information for use in clinical medicine. HyperMed has conducted research in the areas of shock and breast cancer in addition to the studies of patients with diabetic foot ulcers and peripheral arterial disease. HyperMed is at the forefront medical hyperspectral technology, with 7 issued and 19 pending and provisional patents.

HyperMed's fundamental research has been funded through the support of the Juvenile Diabetes Research Foundation, the US Army, NASA, the National Institute of Diabetes and Digestive and Kidney Diseases division of the National Institutes of Health and the Type 1 Diabetes Research Special Statutory Funding Program.

HyperMed's approach and technology has been presented at numerous national and international meetings including the American Diabetes Association, the American Heart Association, American Association for the Surgery of Trauma, and the World Congress of Cardiothoracic Surgery and published in numerous journals, including The Lancet, The Journal of Trauma and Microvascular Complications Today.

http://www.hypermed-inc.com/